Plifosir®
Ibrutinib
Therapeutic action
Antineoplastic protein kinase inhibitors
Indications
- Mantle cell lymphoma
- Chronic lymphocytic leukemia
- Small lymphocyte lymphoma
- Chronic lymphocytic leukemia
- Small lymphocyte lymphoma with 17p deletion
- Waldenström macroglobulinemia
- Marginal zone lymphoma
Presentation
Hard capsules of 140 mg.